NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









G+FLAS Life Sciences

G+FLAS Life Sciences

Private
South KoreaHealthcare & Life Scienceshttps://www.gflas.com/

Last Round

Series C

Sep 3, 2019

Total Funding Raised

$28M

Company Overview

G+FLAS Life Sciences is a biotechnology company that develops new drugs, biopharmaceuticals, and novel seeds based on CRISPR gene editing technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

genome editingCRISPRgene editing platformplant-based biologicsmolecular farmingCRISPR-PLUSnon-GMO plant editingbiobettersgenome editing servicescontract research organizationCROCRISPR reagentsagritechbiosimilarsglycoengineeringbiofortificationCas12a

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

G+FLAS Life Sciences Comps

Public and private peers based on sector, stage, and business model.

G+FLAS Life Sciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

G+FLAS Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 3, 2019
Series BJul 19, 2018
Series AMar 1, 2017
SeedMar 1, 2016

G+FLAS Life Sciences Investors

Notable investors and investment history

G+FLAS Life Sciences investors
InvestorRounds
Smilegate InvestmentSeries C
The Wells InvestmentSeries A
ActnerLabSeed
Alpen RouteSeries C
DS Asset ManagementSeries B
Timefolio Asset ManagementSeries B
Daesung Private EquitySeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors grew 169% MoM, reaching 6.2K.

  • May 2, 2025

    Monthly visitors grew 36% MoM, reaching 1.5K.

G+FLAS Life Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

G+FLAS Life Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about G+FLAS Life Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea
Employee Range8
Year Founded2016
Last FundingSep 3, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.